Crizotinib: ALK/MET/ROS1 Inhibitor for Cancer Research
Explore crizotinib's mechanism, selectivity, and research applications as a potent ALK, MET, and ROS1 tyrosine kinase inhibitor for oncology studies.
主题
non-small cell lung cancer
以下是知识库中与该主题相关的实验方案、常见问题、指南与技术文章。
2 项资源 · 实验方案、常见问题与文章
Molecular Classification, Oncogenic Drivers, and Resistance Mechanisms of Non-Small Cell Lung Cancer
Non-small cell lung cancer exhibits substantial histological and molecular heterogeneity. Alterations involving EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, HER2, and other oncogenic drivers can continuously activate tumor-cell proliferation and survival signaling and generate molecular subtypes with ...
相关主题
同一批资源中共同出现的其他主题。
危险品化学品经营许可证（带存储）